# Study to Assess the Effect of Hepatic Impairment on the Pharmacokinetics of CTP-543

> **NCT05467722** · PHASE1 · COMPLETED · sponsor: **Concert Pharmaceuticals** · enrollment: 21 (actual)

## Conditions studied

- Hepatic Impairment

## Interventions

- **DRUG:** CTP-543

## Key facts

- **NCT ID:** NCT05467722
- **Lead sponsor:** Concert Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-06-01
- **Primary completion:** 2022-09-15
- **Final completion:** 2022-09-21
- **Target enrollment:** 21 (ACTUAL)
- **Last updated:** 2022-11-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05467722

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05467722, "Study to Assess the Effect of Hepatic Impairment on the Pharmacokinetics of CTP-543". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT05467722. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*